MeiraGTx Holdings plc has acquired privately held Vector Neurosciences Inc. in an all-stock transaction.

The acquisition adds a mid-stage gene therapy program to MeriaGTx's portfolio dubbed adeno-associated virus encoding glutamic acid decarboxylase for the treatment of Parkinson's disease. In a phase 2 clinical trial, the therapy has shown promising results when compared to placebo.

"This strategic acquisition gives us an exciting mid-stage product candidate with promising, sham-controlled clinical data and expands our portfolio of potential therapies for neurodegenerative diseases," said MeiraGTx President and CEO Alexandria Forbes.

Financial details of the acquisition were not disclosed.